Showing results (81-90 of 280) with videos related to

Sort By:
Pageof 28
Clinical Genitourinary Cancer|February 25, 2015
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate CancerTian Zhang, Mallika S Dhawan, Patrick Healy, et al.
Cancer Research|October 17, 2014
Copper signaling axis as a target for prostate cancer therapeuticsRachid Safi, Erik R Nelson, Satish K Chitneni, et al.
Advances in Therapy|March 1, 2020
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus PrednisoneKrishnan Ramaswamy, Stanislav Lechpammer, Jack Mardekian, et al.
Urologic Oncology|July 10, 2026
Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United StatesDaniel J George, Furaha Kariburyo-Yay, Himani Aggarwal, et al.
The American Journal of Managed Care|September 20, 2024
Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costsDeborah R Kaye, Hui-Jie Lee, Alexander Gordee, et al.
Journal of Medical Economics|January 11, 2024
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiationDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
Molecular Cancer Research : MCR|July 28, 2026
3beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancerMasoud Bitaraf, Mohammad Alyamani, Nikou Fotouhi, et al.
JCO Oncology Practice|January 23, 2023
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate CancerDeborah R Kaye, Hui-Jie Lee, Alexander Gordee, et al.
Ophthalmology|September 5, 2002
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416Lloyd Paul Aiello, Daniel J George, Mark T Cahill, et al.
The Journal of Urology|July 27, 2011
Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancerSimon J Hall, Laurence Klotz, Allan J Pantuck, et al.
Pageof 28